Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UPDATE: Tuya Q3 Adj. EPS $(0.03), Inline

Tuya (NYSE:TUYA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.06) per share from the same period last year. The company
byBenzinga Newsdesk
November 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Tuya (NYSE:TUYA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $45.02 million which beat the analyst consensus estimate of $44.11 million by 2.05 percent. This is a 47.40 percent decrease over sales of $85.58 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

SVB Financial’s Earnings Outlook

By Benzinga Insights
July 20, 1:05 PM
SVB Financial (NASDAQ:SIVB) is set to give its latest quarterly earnings report on Thursday, 2022-07-21. Here's what investors need to know before the announcement. Analysts estimate that SVB Financial will report an earnings per share (EPS) of $8.05.

SIVB

Read More

Rona Therapeutics Announced Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

By Charles Gross
July 25, 5:14 AM
Rona Therapeutics, Inc ("Rona"), a fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, today announced that it has obtained worldwide exclusive rights to Sanofi's siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.

SNY